Pulse Biosciences, Inc. is a biotechnology company specializing in plasma-based, acoustic-assisted tissue treatments, focusing on medical devices and aesthetic treatments utilizing its proprietary CellFX technology.

# Company Summary: Pulse Biosciences, Inc.

**Overview:**  
Pulse Biosciences, Inc. is a biotechnology company focused on developing and commercializing innovative medical and aesthetic treatments using its proprietary technology, CellFX.

**Core Business Activities:**  
- The company develops and sells medical devices and treatment systems that utilize its proprietary acoustic and plasma-based platform, notably the CellFX System.
- The CellFX System is designed for dermatological and other medical applications involving tissue removal, regeneration, or other therapeutic effects.

**Leadership:**  
- Key executives include President and CEO Paul A. LaViolette, Chief Commercial Officer Kevin P. Danahy, CTO Darrin R. Uecker, and Chairman Robert W. Duggan.

**Number of Employees:**  
- The specific number of employees is not explicitly provided in the document.

**Customers and Market Presence:**  
- The document does not specify the number of customers served or current market share.

**Financials (as of FY 2024):**  
- Revenue and net income figures are not disclosed in the provided text.
- Revenue, income, and other financial metrics are not mentioned explicitly; the focus is mainly on corporate governance, executive compensation, and transactions.

**Additional Details:**  
- The company has entered into various employment agreements, equity incentive plans, and financing arrangements, including rights offerings and loans, primarily involving large investors and stakeholders such as Robert W. Duggan.
- The company has a broad executive and board structure, with substantial stock ownership by major shareholders, notably Duggan and Zanganeh.
- The company’s activities include issuing stock options, warrants, and conducting private placements to fund operations.

**Summary:**  
Pulse Biosciences, Inc. is an innovative medical technology firm specializing in plasma-based, acoustic-assisted tissue treatments with a focus on dermatous and potentially other therapeutic applications. Its governance and financial strategies involve significant shareholder investments and employee equity incentives. No specific operational metrics such as employee count, revenue, customer base, or profit figures are included in the provided excerpt.

Pulse Biosciences, Inc. specializes in bioelectric medicine with a focus on its patented Nano-pulse Stimulation (NPS) technology for targeted cell treatment.

# Company Overview: Pulse Biosciences, Inc.

**Business Focus**:  
Pulse Biosciences, Inc. is a bioelectric medicine company specializing in health innovation through its patented **Nano-pulse Stimulation (NPS)** technology. This technology delivers nanosecond-duration pulses of electrical energy aimed at selectively treating targeted cells while sparing surrounding non-cellular tissue.

## Key Technologies:
1. **NPS Technology**:
   - **Description**: Utilizes nanosecond-duration electrical pulses to non-thermally ablate cellular tissue.
   - **Type**: Also referred to as *Nanosecond Pulsed-Field Ablation (nsPFA)* in specific applications.
   - **Application Areas**: Used in various medical specialties, including dermatology, electrophysiology, cardiology, gastroenterology, gynecology, and ear-nose-throat (ENT).

2. **CellFX System**:
   - This is the device platform facilitating the delivery of NPS technology.
   - Initially commercialized for treating benign skin lesions.
   - Transitioned focus towards cardiac applications, particularly for treating atrial fibrillation (AF).

3. **Cardiac Programs**:
   - Pulse Biosciences has developed:
     - **CellFX nsPFA Cardiac Clamp**: For surgical treatment of AF.
     - **CellFX nsPFA 360° Cardiac Catheter**: Unique design for circumferential ablation.
     - **CellFX nsPFA Percutaneous Electrode System**: Used in minimally invasive surgeries.

## Recent Developments:
- As of December 2023:
  - Initiated clinical studies in Prague for the cardiac catheter.
  - Filed 510(k) clearance with the FDA for the cardiac clamp.
  - Received FDA 510(k) clearance for the Percutaneous Electrode System in March 2024.

## Workforce and Participants:
- **Employees**: 
  - As of December 31, 2023, Pulse Biosciences has **56 employees** split between research and development (approximately 50%) and operations/administration (approximately 50%).

## Customer Base:
- **Customers**: 
  - Commercially targeted primarily at healthcare professionals, including cardiologists, surgeons, and medical clinics in various specialties. 
  - Specific customer numbers are not disclosed.

## Financial Metrics:
- **Revenue**: 
  - The company has not generated significant revenue to date. 
  - It has primarily relied on financing from equity and loans to support its operational costs and research.
- **Net Income**: 
  - The company has incurred ongoing operating losses since inception, with expectations of continued losses for upcoming years. 
  - Specific loss figures are not detailed in the provided information but the company expects to face increased costs associated with product development and clinical trials.

## Intellectual Property:
- The company maintains a strong intellectual property portfolio with **197 issued patents** and pending patent applications, along with an exclusive license to **69 additional issued patents**.

## Future Prospects:
- Pulse Biosciences aims to leverage its technology for broader applications beyond cardiology and looks to develop partnerships to further enhance its market reach and offerings.

This summary provides a comprehensive look into Pulse Biosciences, highlighting the company's focus on innovative bioelectric medicine and NPS technology, along with financial and operational details.

PULSE BIOSCIENCES, INC.

10-K / April 30, 2025

10-K / March 28, 2024

10-K / April 30, 2025

Company Summary: Pulse Biosciences, Inc.